Fortress Biotech, Inc. (FBIO)
1.875
-0.12
(-5.78%)
USD |
NASDAQ |
Nov 13, 16:00
1.875
0.00 (0.00%)
After-Hours: 19:59
Fortress Biotech Enterprise Value : -35.02M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | -35.02M |
| November 11, 2026 | -34.36M |
| November 10, 2026 | -37.69M |
| November 09, 2026 | -35.02M |
| November 06, 2026 | -39.69M |
| November 05, 2026 | -40.02M |
| November 04, 2026 | -35.69M |
| November 03, 2026 | -36.69M |
| November 02, 2026 | -37.02M |
| October 30, 2026 | -37.35M |
| October 29, 2026 | -34.69M |
| October 28, 2026 | -36.02M |
| October 27, 2026 | -37.02M |
| October 26, 2026 | -39.02M |
| October 23, 2026 | -37.02M |
| October 22, 2026 | -35.02M |
| October 21, 2026 | -36.69M |
| October 20, 2026 | -36.69M |
| October 19, 2026 | -39.02M |
| October 16, 2026 | -39.02M |
| October 15, 2026 | -37.69M |
| October 14, 2026 | -38.02M |
| October 13, 2026 | -36.35M |
| October 12, 2026 | -31.02M |
| October 09, 2026 | -30.19M |
| Date | Value |
|---|---|
| October 08, 2026 | -31.69M |
| October 07, 2026 | -33.36M |
| October 06, 2026 | -33.02M |
| October 05, 2026 | -31.69M |
| October 02, 2026 | -33.69M |
| October 01, 2026 | -32.36M |
| September 30, 2026 | -30.03M |
| September 29, 2026 | -28.03M |
| September 28, 2026 | -29.03M |
| September 25, 2026 | -25.36M |
| September 24, 2026 | -25.36M |
| September 23, 2026 | -23.36M |
| September 22, 2026 | -19.70M |
| September 21, 2026 | -21.03M |
| September 18, 2026 | -17.70M |
| September 17, 2026 | -17.70M |
| September 16, 2026 | -19.37M |
| September 15, 2026 | -18.37M |
| September 14, 2026 | -17.03M |
| September 11, 2026 | -17.37M |
| September 10, 2026 | -15.70M |
| September 09, 2026 | -13.70M |
| September 08, 2026 | -11.04M |
| September 04, 2026 | -10.71M |
| September 03, 2026 | -11.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 6.429B |
| Nektar Therapeutics | 722.92M |
| DiaMedica Therapeutics, Inc. | 459.81M |
| Journey Medical Corp. | 121.31M |
| ACADIA Pharmaceuticals, Inc. | 2.230B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.602M |
| Revenue (Quarterly) | 18.72M |
| Total Expenses (Quarterly) | 19.19M |
| EPS Diluted (Quarterly) | -0.0779 |
| Gross Profit Margin (Quarterly) | 61.50% |
| Profit Margin (Quarterly) | 3.22% |
| Earnings Yield | 141.7% |
| Normalized Earnings Yield | 130.60 |